New research programmes, clinical-trial support and automated laboratories
New research funding and recruitment programmes, permanent EU trial-application advice and a planned antibody laboratory.
Five specialists select new research papers. Rowan separately reports important news across the field. Each topic can include up to five significant papers per day, and the news digest up to five significant stories.
We publish when there is something worth reading. Dates show when each update was prepared. Our weekly editions bring the deeper reporting and analysis.
New research funding and recruitment programmes, permanent EU trial-application advice and a planned antibody laboratory.
The chemistry Nobel, data for cell models, vaccine and resistance research, a discovery partnership and materials-testing funds.
Biological databases, clinical trials, mRNA manufacturing, broader discovery-tool access and shared pharmaceutical data standards.
FDA consultation, an AI-assisted drug application, expanded molecular-gate research, optogenetics recognition and NHS biomarker testing.
A halted chromatin programme, RNA-editing trial plans, an ADC combination, public research funding and protein-provenance tools.
A first-line leukaemia approval, alternatives to animal tests, critical-mineral projects, antibody software and priorities for women’s health.
Which measurement methods, model tests and interface designs sharpen materials decisions?
Which chemical designs clarify target signaling, payload release and ligand discovery?
Five primary research reports with explicit source-access and validation boundaries.
A first rare-disease approval, an uncertain four-year gene-therapy readout, funded antifungal development, first CAR-T dosing and laboratory imaging software.
Five primary research reports with explicit source-access and validation boundaries.
Which chemical designs and measurement methods connect predictions with reliable material discovery and molecular observation?
Which chemical-design changes improve target selectivity, local exposure and measured engagement?
Five research reports on spectra, molecular design and protein interactions.
Five announcements commit infrastructure, development rights and funding to biological research and drug discovery.
Five studies examine cellular exposure, clinical model choice, nanoparticle infusion, screening reproducibility and thermal antibiotic responses.
Five research reports on purification, reaction prediction and synthetic access.
Which new validation tools make atomistic prediction and electrocatalyst measurements more dependable?
Which new compound-design and assay methods connect molecular changes with measurable binding or cellular performance?
Five research reports on molecular representations, structural inference and analytical identification.
Five company announcements concern clinical development, automated research access and materials manufacturing.
Five studies examine drug-binding pathways, treatment readouts and the consequences of pharmacology model choices.
Five research reports on optimization, adaptive operation and chemical transformations.
Which new physical measurements and simulations change materials design and validation decisions?
Which new compound-design studies connect molecular changes with measured target engagement and useful exposure?
Five studies examine molecular shapes, protein contacts, scarce data and the limits of structural inference.
Public knowledge graphs, semiconductor translation and an AI-designed nanobody award.
Five papers examine how computational choices affect signalling, toxicity screening and treatment-response estimates.
Five studies connect process screening, catalyst kinetics, stereoselectivity and direct synthesis.
Which new model evaluations connect electronic and structural predictions with useful materials evidence?